• 15-PGDH Inhibition Restores Muscle Repair During GLP-1RA Wei

  2026-06-23

  This study demonstrates that inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH) can reverse muscle repair deficits resulting from semaglutide-induced weight loss. By combining a 15-PGDH inhibitor with GLP-1 receptor agonist therapy, the authors show improved muscle stem cell function and enhanced regenerative myofiber growth, suggesting a promising strategy for preserving muscle health during pharmacological obesity treatment.

• GluN2A/2B Regulation of Connexins in TMJ Inflammation and Al

  2026-06-23

  This study elucidates how N-methyl-D-aspartate receptor (NMDAR) subunits GluN2A and GluN2B distinctly regulate connexin and pannexin expression in the trigeminal ganglion during temporomandibular joint (TMJ) inflammation. The findings uncover specific intracellular pathways underlying orofacial inflammatory allodynia and identify new mechanistic targets for pain modulation.

• SR 11302: Precision AP-1 Inhibition for Selective Tumor Cont

  2026-06-22

  Explore SR 11302, a selective AP-1 transcription factor inhibitor, and its unique role in targeted cancer research. This article reveals advanced scientific insights and practical assay implications, distinguishing SR 11302's mechanism and selectivity for modern oncology.

• Polyploid Giant Cancer Macrophages: Markers of Metastatic Pr

  2026-06-22

  The referenced study demonstrates that circulating phagocytic polyploid giant cancer macrophages (CAMLs) are robust, clinically relevant markers of disease progression in diverse solid tumors. Their unique phenotypic features and correlation with metastasis offer new insight into pre-metastatic niche biology, with implications for future inflammation and cancer research.

• Trelagliptin Enhances Osteoblastic Differentiation via RUNX2

  2026-06-21

  This study demonstrates that trelagliptin, a DPP-4 inhibitor, promotes osteoblastic differentiation and mineralization in MC3T3-E1 cells by increasing RUNX2 expression through AMPK signaling. These findings suggest a novel therapeutic avenue for osteoporosis and provide a mechanistic link between diabetes therapies and bone formation.

• Cyclo (-RGDfC) in Precision Tumor Targeting and Integrin Bio

  2026-06-20

  Explore how Cyclo (-RGDfC) empowers integrin-mediated tumor targeting through unique biochemical stability and specificity. This article delves into advanced applications, protocol insights, and critical assay considerations for c(RGDfC) in cancer research.

• Sex-Dependent Effects of SAG on Immune Modulation in CNS Dem

  2026-06-19

  This study explores how the Smoothened agonist SAG differentially modulates peripheral immune responses in male and female models of CNS demyelination. The findings reveal a sex-dependent interplay between Hedgehog and androgen signaling, offering critical insight for designing targeted regenerative and immunomodulatory therapies.

• MCC950 Sodium: Translational Leverage in NLRP3 Inflammasome

  2026-06-19

  This article provides translational researchers with a mechanistic and strategic roadmap for leveraging MCC950 sodium (CRID3 sodium salt) as a benchmark NLRP3 inflammasome inhibitor. We unpack recent in vivo evidence, protocol best practices, and the evolving clinical relevance of NLRP3 inhibition, highlighting APExBIO's MCC950 sodium as a tool of choice for rigorous experimental workflows in inflammatory and autoimmune disease models.

• FPR2/ALX Stimulation Restricts Autoimmune Astrocytopathy via

  2026-06-18

  This study demonstrates that FPR2/ALX activation by Quin-C1 modulates microglia and natural killer (NK) cells, reducing neuroinflammation and demyelination in a mouse model of autoimmune astrocytopathy. The findings highlight the therapeutic potential of targeting FPR2/ALX signaling in neuroinflammatory diseases and underscore the importance of non-denaturing protein extraction in mechanistic studies.

• Cyclophosphamide in Cancer Research: Protocols & Workflow Ad

  2026-06-18

  Cyclophosphamide is a cornerstone alkylating chemotherapeutic agent, uniquely bridging apoptosis induction in cancer cells and advanced immune modulation. This article delivers actionable protocols, troubleshooting tips, and comparative insights—empowering researchers to maximize rigor and reproducibility with APExBIO’s Cyclophosphamide in both traditional oncology and innovative translational workflows.

• Human iPSC-Derived Intestinal Organoids in Pharmacokinetics

  2026-06-17

  This study presents a robust protocol for generating human intestinal organoids from pluripotent stem cells, providing a more physiologically relevant model for pharmacokinetic research. The approach addresses limitations of traditional models by enabling long-term expansion, differentiation, and metabolic profiling of intestinal epithelial cells.

• (+)-Bicuculline: Technical Guide for GABAA Antagonist Resear

  2026-06-17

  (+)-Bicuculline is a selective GABAA receptor antagonist used in neuroscience research to probe GABAergic signaling and synaptic NMDA receptor modulation. It is not intended for diagnostic or medical applications, and reproducible experimental results depend on strict adherence to solubility and storage guidelines.

• Cyclo (-RGDfC) for Integrin αvβ3: Advanced Tumor Targeting W

  2026-06-16

  Cyclo (-RGDfC) empowers precision integrin αvβ3 targeting in cancer research, delivering robust cell adhesion, migration, and drug delivery workflows. Explore optimized protocols, troubleshooting tips, and how recent open-platform hydrogel printing innovations amplify reproducibility and throughput in integrin-mediated assays.

• 15-PGDH Inhibition Restores Muscle Repair During GLP-1 RA We

  2026-06-16

  This study demonstrates that inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH) significantly reverses muscle repair deficits caused by semaglutide-induced weight loss. The findings highlight the potential of 15-PGDH inhibitors to preserve muscle function and promote regeneration during pharmacological obesity treatment.

• Sphingosine-1-phosphate: Guiding Translational Research in V

  2026-06-15

  This thought-leadership article explores the mechanistic role of sphingosine-1-phosphate (S1P) in cell survival, vascular maturation, and apoptosis, with a focus on translational implications for researchers. Integrating mechanistic insights, recent evidence, and strategic guidance, the piece contextualizes S1P's value in experimental and clinical settings, highlighting APExBIO's S1P as a trusted reagent. The discussion bridges emerging findings in neuronal apoptosis with established vascular signaling paradigms, offering actionable protocol advice and a forward-looking outlook for translational scientists.

439 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page